Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06627699

Prospective, In-Vivo, Post-Market Safety and Efficacy Surveillance Registry of the MAXX Orthopedics, Freedom Total Knee® System

In an effort to satisfy regulatory requirements for post-market surveillance of product safety and efficacy, a representative sample of patients will be recruited for prospective monitoring.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ascentist Healthcare, Leawood, Kansas, United States

Loading trial locations.

About this study

In an effort to satisfy regulatory requirements for post-market surveillance of product safety and efficacy, a representative sample of patients will be recruited for prospective monitoring.

To maintain equal site distribution per device, patient recruitment will include up to a total of twenty (20) registry sites and thirty (30) primary TKA candidates per site / surgeon for a total of 600 registry patients. A total of no more than 200 patients across all sites will be recruited per level of constraint (e.g.: 200 CR, 200:PS, 200:UC) for this registry with a 10-month accrual target from study initiation per site (~3 patients consented / month).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Candidates for this registry must meet ALL of the following criteria:

  • Patient is > 18 years of age
  • Patient has failed attempts at non-operative conservative therapy
  • Patient has participated in the informed consent process and signed an IRB approved informed consent
  • Patient is scheduled to undergo unilateral or bilateral primary TKA of the knee

Exclusion criteria

Candidates will be excluded from the evaluation if ANY of the following apply:

  • Patients with previous TKA, UKA, HTO or knee fusion of the indicated knee
  • Patients that have undergone previous surgery of indicated knee for tumor, trauma or fracture
  • Evidence of active or suspected (systemic or local) infection at time of surgery
  • Other significant disabling problems from the musculoskeletal system than in the knee (i.e.: muscular dystrophy, polio, neuropathic joints)
  • Patients with or having; malignancy - active malignancy, Paget's disease, renal osteodystrophy, immunologically suppressed, sickle cell anemia and systemic lupus erythematosus
  • Patients with neuromuscular or neurosensory deficit
  • Women who are pregnant
  • Prisoner or transient
  • Recent history of known narcotic abuse
  • Any significant psychological disturbance past or present, that could impair the consent process or ability to complete subject self-report questionnaires

Treatment and study plan

Total knee arthroplasty

Device

Post-Market Surveillance of the Freedom Total Knee System for Primary TKA

Primary outcomes

  1. Device Survivorship

    Time frame: 2 years

    Revision / re-operation post-operatively due to device / device composite failure. An anticipated benefit of the device is that it is more conforming at higher degrees of flexion, which could potentially result in reduced polyethylene wear and improved survivorship over the longer-term. To assess this aspect of the device in addition to safety over the short-, intermediate- and long-term, survivorship analyses will be conducted at the targeted follow-up landmark timepoints.

    There will be 3 survivorship endpoints:

    • Revision of any component (including insert) for any reason
    • Revision of any component (including insert) for any reason except infection

Secondary outcomes

  1. Original Knee Society Scale (KSS)

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    The Knee Society Score rating system was first introduced during the late 1980's and has become the standard clinical evaluation system for reporting results for patients undergoing Total Knee Arthroplasty. Most major journals strongly encourage that total knee manuscripts include Knee Society Score rating scores as part of the result section. The Knee Society Score consists of points given for pain, range of motion, and stability. The Function Score consists of points given for the ability to walk on level surfaces, and the ability to ascend and descend stairs, with deductions for the use of external supporting devices.

  2. Knee Injury and Osteoarthritis Outcome Score - Joint Replacement (KOOS-JR)

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    The KOOS-JR is self-administered and assesses three domains: stiffness (1 question), pain (4 questions), function / daily living (2 questions). The KOOS-JR meets basic criteria of outcome measures and can be used to evaluate the course of knee injury and treatment outcome. Each item (questions) is coded from 0 to 4. The raw responses are summed (0-28) which is then converted to an interval score based on the KOOS-JR conversion table. The score is a percentage score from 0 to 100, 0 representing total knee disability and 100 representing perfect knee health.

  3. Patient Reported Outcomes Measurement Information System (PROMIS Global-10)

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    The Patient Reported Outcomes Measurement Information System (PROMIS Global-10) is a valid and reliable patient assessment and consists of ten (10) items that measure physical health, physical functioning, general mental health, emotional distress, satisfaction with social activities and relationships, ability to carry out usual social activities and roles, pain, fatigue and overall quality of life. The response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient. The PROMIS 10 scores are predictive of healthcare utilization, mortality in general and disease-specific clinical populations.

  4. Visual Analog Scale (VAS)

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    This scale has been designed to give subjective pain information as to the degree of knee pain you the patient is currently experiencing. VAS scoring is included in the PROMIS GLOBAL-10 assessment and is not necessary to collect a separate assessment. Applying the VAS, the patient will select a number from 1 (no pain) to 10 (maximum pain) that most closely describes their current pain.

  5. Forgotten Joint Score (FJS-12)

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    The 12 question Forgotten Joint Score (FJS-12) was introduced with the aim of assessing the patients 'joint awareness'. The authors of the score suggest the "higher the score" is more representative of higher-level function after surgery, as to be able to forget about the joint requires the absence of pain and the ability to perform all desired functional tasks without limitation.

Other outcomes

  1. Radiography (plain-film radiography as per standard of care - independent collective site assessment)

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    • Evidence of correct component position
    • Evidence of stable component fixation
    • Review of incidence and location of any lucencies, sclerotic lines, component subsidence and/or osteolysis
  2. Adverse Events

    Time frame: 3-6 Weeks, 3 Months, 6 Months, 12 Months, 24 Months

    • Local (wound and skin)
    • Systemic (infection markers)
    • Clinical / radiographic evidence of component / composite failure
    • Unscheduled re-visit or re-operation within 24 months post-operatively.

Study contacts

Contact information is provided by the study sponsor or research team.

Corey Perine, BS, MBA

CONTACT

[email protected]

215-432-4323

Nach Dave, MS, RPh

CONTACT

[email protected]

732-718-1385

Sponsors and collaborators

Lead sponsor

Maxx Orthopedics Inc

Industry

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Oct 4, 2024
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.